Phase I clinical trial of vaccination with URLC10-derived peptide for patients with advanced esophageal cancer

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy

(2011) Christiane Maria Rosina Thallinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma

(2010) Makoto Iwahashi et al.   CANCER SCIENCE

Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

(2009) Andrew J. Rech et al.   Annals of the New York Academy of Sciences

T-regulatory cell modulation: the future of cancer immunotherapy?

(2009) S Nizar et al.   BRITISH JOURNAL OF CANCER

Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer

(2009) Koji Kono et al.   CANCER SCIENCE

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

(2008) M. A. Morse et al.   BLOOD

Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission

(2008) C. S.M. Diefenbach et al.   CLINICAL CANCER RESEARCH

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET